Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Schommers

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Current Opinion in Virology|March 20, 2022
Broadly neutralizing antibodies against HIV-1 and concepts for applicationHenning Gruell, Philipp Schommers
The Lancet. Infectious Diseases|July 22, 2024
The need for novel approaches to HIV-1 vaccine developmentClara Lehmann, Philipp Schommers
The Lancet. HIV|October 6, 2023
Advancing bnAb combinations for HIV preventionHenning Gruell, Philipp Schommers
Signal Transduction and Targeted Therapy|October 14, 2024
Therapeutic interfering particles against HIV: molecular parasites reducing viremiaHenning Gruell, Stanley Odidika, Philipp Schommers
Frontiers in Immunology|January 21, 2025
Current methods for detecting and assessing HIV-1 antibody resistanceStanley Odidika, Martin Pirkl, Thomas Lengauer, et al.
Frontiers in Immunology|January 7, 2022
Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and PreventionKshitij Wagh, Marit J van Gils, Harry Gristick, et al.
Journal of Virology|March 19, 2024
Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodiesPascal von Maltitz, Lukas Wettstein, Tatjana Weil, et al.
Nature Protocols|May 26, 2021
Effective high-throughput isolation of fully human antibodies targeting infectious pathogensLutz Gieselmann, Christoph Kreer, Meryem Seda Ercanoglu, et al.
British Journal of Haematology|May 7, 2021
Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort studyMarcus Hentrich, Markus Müller, Christoph Wyen, et al.
Blood Advances|March 5, 2026
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphomaMarie Anne-Catherine Neumann, Jessica Schneider, Max Szameitat, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Current Opinion in Virology|March 20, 2022
Broadly neutralizing antibodies against HIV-1 and concepts for applicationHenning Gruell, Philipp Schommers
The Lancet. Infectious Diseases|July 22, 2024
The need for novel approaches to HIV-1 vaccine developmentClara Lehmann, Philipp Schommers
The Lancet. HIV|October 6, 2023
Advancing bnAb combinations for HIV preventionHenning Gruell, Philipp Schommers
Signal Transduction and Targeted Therapy|October 14, 2024
Therapeutic interfering particles against HIV: molecular parasites reducing viremiaHenning Gruell, Stanley Odidika, Philipp Schommers
Frontiers in Immunology|January 21, 2025
Current methods for detecting and assessing HIV-1 antibody resistanceStanley Odidika, Martin Pirkl, Thomas Lengauer, et al.
Frontiers in Immunology|January 7, 2022
Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and PreventionKshitij Wagh, Marit J van Gils, Harry Gristick, et al.
Journal of Virology|March 19, 2024
Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodiesPascal von Maltitz, Lukas Wettstein, Tatjana Weil, et al.
Nature Protocols|May 26, 2021
Effective high-throughput isolation of fully human antibodies targeting infectious pathogensLutz Gieselmann, Christoph Kreer, Meryem Seda Ercanoglu, et al.
British Journal of Haematology|May 7, 2021
Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort studyMarcus Hentrich, Markus Müller, Christoph Wyen, et al.
Blood Advances|March 5, 2026
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphomaMarie Anne-Catherine Neumann, Jessica Schneider, Max Szameitat, et al.
Pageof 7